Jakafi 5 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB26FNMMY
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,294
Award facts
- Contract value 100% obligated
- $24,293.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $24,293.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on October 21, 2025, for the supply of Jakafi (ruxolitinib) 5 mg tablets in quantities of 60 units. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order is scheduled for completion by October 22, 2025, with performance to be executed at the contractor's Park Ridge location.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The underlying IDC, valued at $499.999 billion with a term extending through December 31, 2036, authorizes DLA to issue firm fixed-price delivery orders for pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide. As a regional prime vendor contractor under the broader $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group has demonstrated substantial federal contracting activity and capability across a comprehensive portfolio of branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals.
Quick answers
Who was awarded contract SPE2DB26FNMMY?
SPE2DB26FNMMY was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 21, 2025.
How much is contract SPE2DB26FNMMY worth?
The government has obligated $24,294 on SPE2DB26FNMMY.
Is contract SPE2DB26FNMMY an order under another contract?
Yes. SPE2DB26FNMMY is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB26FNMMY competed?
The extent of competition for SPE2DB26FNMMY was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award